



4Q and full-year 2020 financial results

4Q 2020

Worldwide sales
\$12.5 billion

GAAP EPS
\$(0.83)

Non-GAAP EPS
\$1.32

2021 Financial outlook

Anticipates full-year 2021 worldwide sales to be between \$51.8 billion and \$53.8 billion, including a positive impact from foreign exchange of approximately 2%

Expects full-year 2021 GAAP EPS to be between \$5.52 and \$5.72; expects non-GAAP EPS to be between \$6.48 and \$6.68, including a positive impact from foreign exchange of approximately 3%

Key growth drivers

Oncology

KEYTRUDA®

Higher sales and continued uptake



Hospital Acute Care

bridion

Higher demand globally

Animal Health



Higher demand in companion animal vaccines and parasiticides



“Despite extraordinary challenges brought on by the COVID-19 pandemic, Merck achieved solid growth and made meaningful progress in our pipeline in 2020. We remain focused on our science-led strategy and are confident that this approach will continue to deliver value to patients and shareholders.

Our scientists continue to advance our internal pipeline of promising medicines and vaccines, including in oncology, HIV, and pneumococcal disease, and, more recently, therapeutics for COVID-19. These pipeline developments provide us with increasing line-of-sight to significant potential growth drivers later this decade and into the next.”

Ken Frazier
Chairman & CEO

Creating long-term value for patients, employees and shareholders

See investors.merck.com for Merck’s full 4Q earnings release issued February 04, 2021, the associated webcast presentation, forward-looking statement, definitions of non-GAAP measures and reconciliations to the most closely related GAAP measure.